Medigene is responsible for the clinical development of Veregen®, for which it obtained approval, and which is used in the treatment of genital warts. The ointment is marketed globally by business partners.
Medigene is currently conducting research into the application of AAVLP technology for the treatment of cancer and viral infections, and is examining the possibility of using AAV libraries to systematically identify suitable vaccine candidates.
“Medigene has changed substantially. Through the transformative acquisition of Trianta and with partnerships secured for EndoTAG®-1 and RhuDex® we have shaped new prospects for Medigene focused on cutting-edge cancer immunotherapies. Our goal is to build a franchise in hematological malignancies with our own development programs and to offer further development options in solid tumours to selected partners.”